FREMONT, Calif.—Tomorrow, Dr. David Kita, Vice President of R&D at Verseon, will present preclinical results on the Company’s novel class of potent, highly selective direct thrombin inhibitors at the 2017 BIO-Europe Spring conference in Barcelona.

Verseon has developed multiple, chemically diverse drug candidates that show efficacy comparable to the NOACs in preclinical models of arterial and venous thromboembolism, but do not disrupt platelet function. This distinguishing feature provides a biological explanation for the reduced bleeding risk of the Verseon inhibitors observed in preclinical testing.

The presentation will also cover Verseon’s first development candidate for clinical trials. The candidate has pharmacokinetics suitable for oral dosing and is well tolerated even at high doses in single and repeat dosing studies. Furthermore, this development candidate exhibits very low renal clearance in preclinical studies, a highly desirable property for patients with impaired kidney function.

“Our drug candidates effectively inhibit thrombosis while preserving hemostasis, striking a balance that is lacking in current anticoagulants. This leads to the remarkably safe bleeding profile of our candidates that will make them best-in-class therapeutics,” said Dr. Kita.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.